Project Grant R43DA058603
Award Date
9/30/24
Completion Date
9/29/25
Dollars Obligated
$275K
Federal Agency
National Institute on Drug Abuse
Awardee
Epivario Inc. (M6ZTFQ3K1WT3)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression during chronic opioid exposure, and biophysically characterize their drug-protein interactions. The efficacy...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $295,325 to Epivario Inc. to develop a novel small molecule inhibitor of the metabolic enzyme ACSS2 as a potential treatment for cocaine use disorder (CUD). The key objectives are to assess the pharmacological properties, including selectivity, efficacy on epigenetic regulation, and pharmacokinetics, of Epivario's lead ACSS2 inhibitor...
This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $11,872,077.00 in funding to Sparian Biosciences Inc. (doing business as Palion Therapeutics) for the development of SBS-226, a novel mu-opioid receptor agonist and delta-opioid receptor antagonist, as a treatment for opioid use disorder (OUD). The research project, spanning from September 2024 to August 2026, aims to characterize...
This $716,226 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel small molecule allosteric modulators targeting the neurotensin receptor 1 (NTSR1) as a potential treatment for opioid use disorder (OUD). The overarching goals are to: 1) validate NTSR1 as a viable drug target for treating OUD, and 2) discover next-generation NTSR1 modulators with improved selectivity for...
This $858,600 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh. The grant aims to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex that could be targeted for developing new treatments for opioid use disorder (OUD). The research will use an unbiased transcriptomics approach to identify...
This $419,876 Project Grant was awarded on September 15, 2024 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will support preclinical research to investigate the therapeutic potential of targeting the neuropeptide S (NPS) receptor to mitigate opioid addiction. Specifically, the grant aims to: 1) Determine if NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation to obtain the drug in...
This $715,238 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a large-scale genome-wide association study (GWAS) of opioid-related traits in a diverse population of 500,000 individuals. The University of California, San Diego (UCSD) is the primary awardee and will work to uncover the genetic basis of the pre-addiction stages of opioid use, such as initial use, subjective response, and...
This $159,711 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a study titled "Electrophysiological Dynamics of Acute Opioid Use in Human Reward, Affect, and Pain Pathways." The project aims to investigate how acute opioid administration impacts neural connectivity within brain regions associated with opioid use disorder (OUD), including the amygdala, hippocampus, prefrontal cortex, and pain...
This $601,612 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the role of the habenula-interpeduncular nucleus (IPN) circuit in the development of opioid tolerance and withdrawal. The project will use viral approaches, ribosome profiling, and calcium imaging in mice to examine gene expression changes and neuronal activity in the IPN in response to chronic oxycodone exposure. The...
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $267,310 Project Grant to the Regents of the University of Minnesota to investigate the role of the neuropeptide VGF and its derived peptide TLQP-62 in regulating synaptic plasticity in the nucleus accumbens and their contribution to opioid withdrawal behaviors. The project aims to use electrophysiology, neuroanatomical mapping, and behavioral assays to understand how VGF...